Recurring revenue of 7.4 million is huge! If you extrapolate recurring revenue out over 4 quarters, by itself, you get almost to 95% of the market cap of the company before today's 11 cent move. Short explanation.. this stock is dramatically undervalued even without considering today's Q4 results and Epoch being a game changer for hesitant physicians
You are incorrect - they do get those reveneus, but some of them (the Biosense Webster royalties) now go to pay off the Cowen debt. Obviously the recurring rev's are not all coming from Biosense royalties.
Once Cowen is paid off then they get "all" of it (to pay off lord knows what other debts...)
HNSN did 1700 cases last year. STXS over 10,000. hmmmmmm..... HNSN 3.00 STXS under a buck hmmmm. STXS new Epoch system (10 in first Q of release) with in market data and adoption HNSN protoype for vascular not even being used in US to any degree hmmmmm....